Scarica l'app Stockscreener
0.1899
1.20%
-0.0023
Dopo l'orario di chiusura:
.20
0.0101
+5.32%
Kala Bio Inc Borsa (KALA) Ultime notizie
KALA Bio Inc.: KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception - FinanzNachrichten.de
A telehealth platform has generated over $48 million in sales since 2023. KALA Bio may buy it. - Stock Titan
Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products - Yahoo Finance
Kala Pharmaceuticals Inc (NYSE: KALA) Share Price, KALA Stock News, KALA Share Price & Updates - kalkine.ca
Kala Pharmaceuticals Inc (NYSE: KALA) Share Price, KALA Stock News, KALA Share Price & Updates - Kalkine
KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team - Yahoo Finance
Reverse stock split heads to a vote at KALA BIO (NASDAQ: KALA) - Stock Titan
Kala Bio announces annual shareholder meeting - Bitget
Kala Bio signs exclusive US distribution deal with Virotek for ophthalmology genetic testing - Investing.com
Kala Bio signs exclusive US distribution deal with Virotek for ophthalmology genetic testing - Investing.com India
Kala Bio signs exclusive US distribution deal with Virotek for ophthalmology genetic testing - Investing.com UK
Kala Bio Secures Exclusive Ophthalmic Genetic Testing Deal - TipRanks
Kala Bio Secures 5-Year Exclusive U.S. Distribution for Ophthalmic Genetic Testing With Virotek - tradingview.com
KALA BIO, Inc. Enters Exclusive Distribution And Reseller Agreement With Virotek, Inc - marketscreener.com
KALA BIO (NASDAQ: KALA) Announces November 3, 2026 Annual Meeting and September 19 Proposal Deadline - Kalkine Media
KALA BIO Updates Annual Meeting and Proposal Deadlines - TipRanks
KALA BIO (NASDAQ: KALA) sets Sept. 19 cutoff for 2026 shareholder proposals - Stock Titan
Kala Bio secures exclusive U.S. rights to Virotek genetic tests By Investing.com - Investing.com Nigeria
KALA Stock Update: Exclusive U.S. Distribution Deal with Virotek Highlights Growth Challenges - GuruFocus
Kala Bio Signs Exclusive U.S. Distribution Agreement for Virotek Ophthalmology Genetic Tests - Yahoo Finance
Kala Bio secures exclusive U.S. rights to Virotek genetic tests By Investing.com - Investing.com South Africa
Kala Bio secures exclusive U.S. rights to Virotek genetic tests - Investing.com
Kala Bio and Virotek Finalize Definitive Agreement - GlobeNewswire
Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program - Yahoo Finance
Kala Bio Targets Near-Term Revenue With Virotek Ophthalmology Genetic Testing Partnership - finance.yahoo.com
Kala Bio, Virotek enters LOI for distribution agreement - TipRanks
KALA Bio (KALA) Signs Exclusive Distribution LOI with Virotek, F - GuruFocus
Kala Bio, Virotek Outline Exclusive U.S. Genetic Testing | KALA Stock News - Stock Titan
Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program - Yahoo Finance
KALA BIO Faces Nasdaq Listing Compliance Uncertainty - The Globe and Mail
KALA BIO Faces Nasdaq Listing Compliance Uncertainty - The Globe and Mail
KALA BIO Faces Nasdaq Delisting Risk on Minimum Bid Price Failure - Minichart
KALA BIO Faces Nasdaq Listing Compliance Uncertainty - TipRanks
KALA BIO Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Aimwell Bio pays in shares, not cash, for Trustr technology and begins naming contributors - Stock Titan
KALA (KALA) Close: Ends Down by 2.39% at $0.82 at the Close; Boundary Watch: Traders Can Monitor the $0.78-$0.86 Range in the Latest ReadingLow Vol ETF - vinanet.vn
Kairos Pharma Announces 1-for-7 Reverse Stock Split - Yahoo Finance
KALA (KALA) Technicals: Moves 6.67% Down to $0.84; Technical Setup: the Supplied Trading Band Runs From $0.80 to $0.88 at the CloseProtective Put - vinanet.vn
KALA BIO Q2 Net Loss Narrows to $1.58 Million Amid Sharp Spending Cuts - Minichart
KALA BIO: Q2 Earnings Snapshot - AOL.com
KALA BIO: Q2 Earnings Snapshot - KTVB
KALA BIO, Inc. Q2 2026: Net loss $(1.58M), EPS $(21.32) — 10-Q Summary - TradingView
KALA: Net loss narrowed sharply as focus shifted to AI platform, with liquidity supported by note receivable - TradingView
KALA BIO (KALA) pivots to biotech AI with $229K on hand - Stock Titan
KALA (KALA) Session: Retreats 0.97% to $0.89; Next Session: Price Remains Between $0.85 Support and $0.93 Resistance in the Latest ReadingRTH Profile - vinanet.vn
K Wave Media Ltd. Announces Pricing of $1.0 Million Registered Direct Offering - Yahoo Finance
KALA Q4 2025 Earnings: Loss Narrows to -33.5 Per Share, Beating Estimates by 54.38Performance Review - vinanet.vn
KALA BIO Announces Brief Delay in Quarterly Filing - TipRanks
KALA BIO (KALA) delays June 30, 2026 Form 10-Q to finalize liquidity analysis - Stock Titan
KALA Q4 2025 Earnings: Narrower-Than-Expected Loss Delivers a 54.38 EPS SurpriseDividend Growth Analysis - vinanet.vn
4.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):